Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Part of Leukemia

23 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Acute Lymphoblastic Leukemia

103 trials tracked for Acute Lymphoblastic Leukemia: 22 in phase 3 or 4 and 16 with published results. The most-cited published study has 349 citations.

103Trials tracked
22Phase 3 & 4
0Recruiting
16With published results
Phase distribution
Phase 4 4 Phase 3 18 Phase 2 62 Phase 1 10 Other / NA 9
  1. Phase 3 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) Completed · 349 cited
  2. Phase 3 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 245 cited
  3. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 230 cited
  4. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 114 cited
  5. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 101 cited
  6. Phase 3 Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Completed · 91 cited
Show 44 more trials
  1. Phase 3 A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia Completed · 79 cited
  2. Phase 3 A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase Completed · 54 cited
  3. Phase 3 Phase III B in Acute Lymphoblastic Leukemia Completed · 51 cited
  4. Phase 3 Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed · 49 cited
  5. Phase 3 An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Completed · 35 cited
  6. Phase 3 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 33 cited
  7. Phase 4 Vaccinating Children After Chemotherapy Completed · 25 cited
  8. Phase 4 A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Completed · 17 cited
  9. Phase 3 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Completed · 12 cited
  10. Phase 3 Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed · 11 cited
  11. Phase 4 A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed
  12. Phase 4 Learning Impairments Among Survivors of Childhood Cancer Completed
  13. Phase 3 Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Completed
  14. Phase 3 Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed
  15. Phase 3 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed
  16. Phase 3 A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors Completed
  17. Phase 2 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Completed
  18. Phase 2 Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Completed
  19. Phase 2 Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies Completed
  20. Phase 2 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Completed
  21. Phase 2 Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Completed
  22. Phase 2 Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults Completed
  23. Phase 2 Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation Completed
  24. Phase 2 Treatment of Adult Ph+ LAL With BMS-354825 Completed
  25. Phase 2 Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies Completed
  26. Phase 2 Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor Completed
  27. Phase 2 Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Completed
  28. Phase 2 ALL Adult Consortium Trial: Adult ALL Trial Completed
  29. Phase 2 Treatment of Older Adults With Acute Lymphoblastic Leukemia Completed
  30. Phase 2 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Completed
  31. Phase 2 Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation Completed
  32. Phase 2 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
  33. Phase 2 Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia Completed
  34. Phase 2 Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Completed
  35. Phase 2 A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) Completed
  36. Phase 2 Sitagliptin Umbilical Cord Blood Transplant Study Completed
  37. Phase 2 Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage Completed
  38. Phase 2 Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia Completed
  39. Phase 2 Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed
  40. Phase 2 Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Completed
  41. Phase 2 Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia Completed
  42. Phase 2 A Study in Adults With Untreated Acute Lymphoblastic Leukemia Completed
  43. Phase 2 Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients Completed
  44. Phase 2 CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) Completed

Showing the 50 most-cited and recently-updated of 103 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Acute Lymphoblastic Leukemia: what the trials found

Several targeted and chimeric antigen receptor (CAR) therapies have demonstrated efficacy in patients with Acute Lymphoblastic Leukemia. Blinatumomab showed significant improvements in event-free survival (EFS) 7 and high rates of hematological response, including CR/CRh* or CRi, during the first two treatment cycles 20. Inotuzumab ozogamicin demonstrated a significantly higher percentage of patients achieving hematologic remission compared to standard treatments 13, with 81.8% to 47.7% reaching CR or CRi depending on the cohort 5. Additionally, Calaspargase Pegol-mknl was associated with high rates of complete remission at the end of induction (92.4% to 97.6%) and favorable event-free survival 16.

Asparaginase remains a cornerstone of treatment; studies show that its use, particularly in combination with other agents like Dasatinib, significantly impacts minimal residual disease (MRD) status at the end of induction 8. High-dose versus conventional dose PEG-asparaginase showed comparable rates of continuous complete remission 12. Additionally, while some trials investigated the impact of Lestaurtinib on MLL-R infants treated with combination chemotherapy and Asparaginase, no significant difference in event-free survival was observed between treatment arms 17.

Clinical assessments of supportive care and complications indicate that Cyclophosphamide is a standard component of therapy [9, 21]. Research into the impact of various agents on complications shows that tacrolimus may reduce the incidence of severe mucositis and acute GVHD compared to other regimens 19, while certain interventions like inotuzumab ozogamicin were associated with low rates of significant laboratory test shifts 4.

Research regarding the physiological impacts of the disease has identified significant differences in brain white matter volume between patients with Acute Lymphoblastic Leukemia and sibling controls, as well as between those with ALL and those with other types of brain tumors 6.

Recent results — preliminary, needs further review

  • Siltuximab was evaluated in a Phase 2 trial (N=24) for the treatment of this condition 1.
  • Cyclosporine was evaluated in a Phase 2 study where the median time to onset of Grade II-IV aGVHD by Day 100 was 34 days 2.

For the clinician treating this condition

  • Blinatumomab and Inotuzumab ozogamicin are established options for achieving high rates of hematologic response and improved event-free survival.
  • Asparaginase remains a core component of treatment, with significant implications for minimal residual disease (MRD) status.
  • Calaspargase Pegol-mknl is associated with high induction remission rates and favorable event-free survival.

AI synthesis of 13 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL
Oncology RCT
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL Trial shows ponatinib and blinatumomab improve outcomes for Philadelphia-positive ALL
In Ph-positive ALL, frontline ponatinib plus blinatumomab achieved 86% 24-month event-free survival versus 67% with imatinib plus chemothera…
A new combination of ponatinib and blinatumomab showed higher survival rates and fewer relapses for adults with Philadelphia-positive ALL.
Oct 15, 2026
Dasatinib therapy in pediatric ALL may cause chylothorax and Bartonella henselae infection
Drug Pipeline Meta-analysis
Dasatinib therapy in pediatric ALL may cause chylothorax and Bartonella henselae infection Dasatinib May Cause Chylothorax and Cat-Scratch Disease in Leukemia
This case report and systematic review describes a 14-year-old boy with Ph+ acute lymphoblastic leukemia treated with dasatinib who develope…
A 14-year-old on dasatinib for leukemia developed chylothorax and cat-scratch disease, a rare double complication.
Frontiers Sep 29, 2026
Blinatumomab Improves Four Year Event Free Survival in Pediatric High Risk B Cell ALL
Oncology RCT
Blinatumomab Improves Four Year Event Free Survival in Pediatric High Risk B Cell ALL Trial shows blinatumomab improves survival for children with high-risk leukemia
Blinatumomab significantly improves 4-year event-free survival in children with high-risk B-cell ALL compared to standard chemotherapy.
A new trial shows that blinatumomab helps more children with high-risk B-cell leukemia stay healthy compared to standard chemotherapy.
Sep 17, 2026
Busulfan-based conditioning favors survival in AML while TBI yields better outcomes in ALL
Pediatrics Meta-analysis
Busulfan-based conditioning favors survival in AML while TBI yields better outcomes in ALL Busulfan Shows Survival Benefits for Patients with Acute Myeloid Leukemia
This meta-analysis of 26 studies compared Busulfan-based conditioning to total body irradiation for children and young adults undergoing hem…
Busulfan may offer better survival for certain leukemias while reducing long-term side effects like growth issues and cataracts in young pat…
Frontiers Sep 17, 2026
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies
Hematology Meta-analysis
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies Bispecific Antibodies Linked to Lower Rates of CMV Infection
This meta-analysis of 23 studies and a single-center cohort evaluated bispecific antibody use in multiple myeloma, B-cell lymphoma, and acut…
New data shows that patients receiving bispecific antibodies for certain blood cancers may have lower rates of serious CMV infections.
Frontiers Aug 27, 2026
IV-PEG asparaginase compared to IM-EC in children with acute lymphoblastic leukemia
Hematology Phase III
IV-PEG asparaginase compared to IM-EC in children with acute lymphoblastic leukemia PEG-asparaginase shows lower toxicity in childhood leukemia trial
This Phase 3 randomized controlled trial evaluated intravenous PEG-asparaginase (IV-PEG) versus intramuscular native E. coli L-asparaginase …
A new trial finds that PEG-asparaginase may cause fewer side effects than standard treatment for children with leukemia.
CT.gov Jul 30, 2026
Asparaginase therapy in acute lymphoblastic leukemia patients correlates with increased thromboembolism risk in specific subgroups
Oncology Meta-analysis
Asparaginase therapy in acute lymphoblastic leukemia patients correlates with increased thromboembolism risk in specific subgroups Adults with Leukemia Show Higher Risk of Blood Clots
This meta-analysis examined the incidence of thromboembolism among patients with acute lymphoblastic leukemia receiving asparaginase based c…
Patients with acute lymphoblastic leukemia treated with asparaginase face higher risks of blood clots, especially adults and those with spec…
Jun 26, 2026
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis
Hematology FDA Approval
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis FDA approves Xatmep for pediatric leukemia and arthritis treatment options
The FDA has approved Xatmep for pediatric patients with acute lymphoblastic leukemia or active polyarticular juvenile idiopathic arthritis. …
The FDA has approved Xatmep to treat specific forms of childhood leukemia and arthritis, offering new options for young patients.
FDA May 30, 2026
Meta-analysis finds fluoroquinolone prophylaxis reduces febrile neutropenia in pediatric ALL
Oncology Meta-analysis
Meta-analysis finds fluoroquinolone prophylaxis reduces febrile neutropenia in pediatric ALL Fluoroquinolone antibiotics lower febrile neutropenia risk in children with acute lymphoblastic leukemia during treatment start
This systematic review and meta-analysis of 991 children with acute lymphoblastic leukemia found that fluoroquinolone prophylaxis reduced fe…
A review of children with acute lymphoblastic leukemia shows fluoroquinolone antibiotics reduce febrile neutropenia risk. This finding sugge…
May 1, 2026
Lyophilized pegaspargase shows similar activity to liquid form in pediatric ALL
Oncology RCT
Lyophilized pegaspargase shows similar activity to liquid form in pediatric ALL Lyophilized pegaspargase shows similar activity and safety to liquid form for pediatric leukemia patients
This phase 2 study in 89 pediatric ALL patients in Russia found that lyophilized pegaspargase had similar maximum plasma asparaginase activi…
A new form of pegaspargase works just like the liquid version for treating acute lymphoblastic leukemia in children in Russia.
May 1, 2026
Meta-analysis links maternal infection in pregnancy to childhood ALL risk
Hematology Meta-analysis
Meta-analysis links maternal infection in pregnancy to childhood ALL risk Maternal Infections During Pregnancy Linked to Higher Risk of Childhood Leukemia
This systematic review and meta-analysis of 26 studies found a modest association between maternal infection during pregnancy and childhood …
A large review of 26 studies found that maternal infections during pregnancy are associated with an increased risk of acute lymphoblastic le…
May 1, 2026
Meta-analysis links perinatal factors to childhood acute leukemia risk
Hematology Meta-analysis
Meta-analysis links perinatal factors to childhood acute leukemia risk Perinatal factors linked to higher leukemia risk in children
This systematic review and meta-analysis of 85 studies examined perinatal factors and childhood acute leukemia risk.
A large analysis of 85 studies finds links between birth weight, maternal history, and cesarean sections with childhood leukemia risk.
May 1, 2026

Research across Leukemia

Related studies from across the Leukemia family.

Early genetic diagnosis of inherited bone marrow failure syndromes facilitates timely transplant and lifelong surveillance
Cardiology Sys. Review
Early genetic diagnosis of inherited bone marrow failure syndromes facilitates timely transplant and lifelong surveillance Genetic Factors May Influence Diagnosis of Bone Marrow Failure
This narrative review explores the pathogenesis, clinical manifestations, and management of pediatric patients with inherited bone marrow fa…
Genetic factors can be the hidden cause of bone marrow failure in children, making early genetic testing vital for proper treatment and plan…
Frontiers Oct 28, 2026
Positive LSC status is associated with inferior survival outcomes in patients with acute myeloid leukemia
Oncology Meta-analysis
Positive LSC status is associated with inferior survival outcomes in patients with acute myeloid leukemia Leukemia Stem Cell Counts Help Doctors Predict Patient Survival Outcomes
This systematic review and reconstructed individual patient data meta-analysis analyzed survival outcomes in patients with acute myeloid leu…
Testing for specific leukemia stem cells can help doctors predict how well a patient will do during treatment.
Oct 27, 2026
Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm
Oncology Sys. Review
Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm Icotinib Treatment for Lung Cancer Linked to Rare Blood Condition
This case report and literature review describes a 75-year-old female with lung adenocarcinoma treated with icotinib. The report identifies …
A rare case of acute myeloid leukemia was linked to a specific lung cancer treatment, highlighting the need for regular blood monitoring.
Frontiers Oct 22, 2026
VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds
Primary Care & Family Medicine Meta-analysis
VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds Vancomycin-resistant Enterococcus is common in patients with certain blood cancers
This meta-analysis of 120 studies estimates the pooled prevalence of vancomycin-resistant Enterococcus (VRE) in patients with hematological …
A large review of 120 studies shows that nearly 1 in 5 patients with leukemia or lymphoma carry a resistant strain of bacteria.
Frontiers Oct 15, 2026
Low-dose chemotherapy shows no difference in remission but worse outcomes in KIT-mutated AML
Oncology RCT
Low-dose chemotherapy shows no difference in remission but worse outcomes in KIT-mutated AML Low-dose chemotherapy shows similar results for some children with leukemia
This retrospective secondary analysis of a multicenter randomized controlled trial evaluated low-dose chemotherapy (LDC) versus standard-dos…
A study of children with a specific type of leukemia found that lower doses of chemotherapy can be as effective as standard doses for many p…
Oct 9, 2026
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients
Hematology Meta-analysis
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients BTK inhibitors do not appear to cause second primary cancers
This meta-analysis of 9337 patients found that BTK inhibitors do not significantly increase the risk of second primary malignancies compared…
New data suggests that a common class of drugs used to treat certain blood cancers does not increase the risk of developing new cancers.
Oct 1, 2026
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia
Pediatrics Meta-analysis
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia Exercise May Help Kids With Leukemia Feel and Move Better
This best evidence summary synthesizes 16 systematic reviews and 2 clinical practice guidelines regarding exercise interventions for childre…
Exercise may improve bone strength, fitness, and quality of life in children with acute leukemia, a new evidence summary suggests.
Frontiers Sep 17, 2026
MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML
Hematology Meta-analysis
MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML Specific gene mutations linked to worse outcomes in certain leukemia
This meta-analysis of 4,363 patients found that MRG mutations (such as ASXL1, BCOR, and EZH2) are associated with inferior overall survival …
New data shows that specific gene mutations can predict poorer survival and lower remission rates for patients with a specific type of leuke…
Sep 1, 2026
Treosulfan-fludarabine improves 24-month event-free survival to 65% versus 53% in AML patients
Hematology RCT
Treosulfan-fludarabine improves 24-month event-free survival to 65% versus 53% in AML patients Treosulfan Shows Better Outcomes for Patients with Acute Myeloid Leukemia
This Phase 3 randomized trial subgroup analysis of 352 patients with AML undergoing alloHCT found treosulfan-fludarabine superior to reduced…
A new analysis of a Phase 3 trial suggests treosulfan may offer better survival rates and fewer complications for patients with acute myeloi…
Sep 1, 2026
Dasatinib 50 mg maintains efficacy while reducing pleural effusion and thrombocytopenia in CP-CML
Hematology Meta-analysis
Dasatinib 50 mg maintains efficacy while reducing pleural effusion and thrombocytopenia in CP-CML Lower Dasatinib Dose May Improve Tolerability for Leukemia Patients
This meta-analysis of 7 nonoverlapping reports compared dasatinib 50 mg and 100 mg in adults with chronic-phase chronic myeloid leukemia. Th…
A lower daily dose of dasatinib may offer similar effectiveness with fewer side effects for adults with chronic-phase chronic myeloid leukem…
Sep 1, 2026
6-month IS value predicts MR4.5 attainment and TKI discontinuation eligibility in CML patients
Hematology Phase III
6-month IS value predicts MR4.5 attainment and TKI discontinuation eligibility in CML patients Trial Shows Early Markers Predict Success in Chronic Myeloid Leukemia
This observational study of 431 patients with chronic myeloid leukemia (CML) on second-generation TKIs found that the 6-month IS value is a …
New data from a Phase 3 trial shows that early markers can help predict which patients with chronic myeloid leukemia may reach specific trea…
Aug 25, 2026
Pirtobrutinib Combined with Venetoclax and Rituximab Improves Progression Free Survival
Oncology RCT
Pirtobrutinib Combined with Venetoclax and Rituximab Improves Progression Free Survival Trial shows pirtobrutinib improves survival for chronic lymphocytic leukemia
Adding pirtobrutinib to a venetoclax-rituximab regimen significantly extends progression-free survival in patients with chronic lymphocytic …
A new combination treatment involving pirtobrutinib may help patients with chronic lymphocytic leukemia live longer without their cancer pro…
Aug 9, 2026

Questions about Acute Lymphoblastic Leukemia

Do factors like age or where a child lives change survival chances for Acute Lymphoblastic Leukemia?

Yes, age and geographic location affect survival in pediatric ALL; younger children and those in high-income countries generally have better outcomes.

Full answer →
Does taking fluoroquinolone medicine help reduce high fevers in children with Acute Lymphoblastic Leukemia?

Fluoroquinolone prophylaxis reduces febrile neutropenia (fever with low white blood cells) in children with ALL, but it is not a treatment for high fevers; it is a preventive measure given during chemotherapy.

Full answer →

All Acute Lymphoblastic Leukemia Articles